Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy

Reetesh K. Pai, Rish Pai

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Neoadjuvant therapy is increasingly used to treat patients with a wide variety of malignancies. Histologic evaluation of treated specimens provides important prognostic information and may guide subsequent chemotherapy. Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used in these tumors and standardized approaches to evaluate these specimens are needed. In this review, the various tumor regression scoring systems that have been used in these organs are described and their associations with clinical outcomes are discussed. Recommendations regarding how to handle and report the histologic findings in these resections specimens are provided.

Original languageEnglish (US)
Pages (from-to)4-23
Number of pages20
JournalModern Pathology
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Neoadjuvant Therapy
Gastrointestinal Tract
Neoplasms
Adenocarcinoma
Pancreatic Ductal Carcinoma
Esophagogastric Junction
Neoplasm Metastasis
Drug Therapy
Pancreatic Carcinoma
Liver
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. / Pai, Reetesh K.; Pai, Rish.

In: Modern Pathology, Vol. 31, No. 1, 01.01.2018, p. 4-23.

Research output: Contribution to journalReview article

@article{1e67bf1d313a479c8f2d87248550bb20,
title = "Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy",
abstract = "Neoadjuvant therapy is increasingly used to treat patients with a wide variety of malignancies. Histologic evaluation of treated specimens provides important prognostic information and may guide subsequent chemotherapy. Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used in these tumors and standardized approaches to evaluate these specimens are needed. In this review, the various tumor regression scoring systems that have been used in these organs are described and their associations with clinical outcomes are discussed. Recommendations regarding how to handle and report the histologic findings in these resections specimens are provided.",
author = "Pai, {Reetesh K.} and Rish Pai",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/modpathol.2017.87",
language = "English (US)",
volume = "31",
pages = "4--23",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy

AU - Pai, Reetesh K.

AU - Pai, Rish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Neoadjuvant therapy is increasingly used to treat patients with a wide variety of malignancies. Histologic evaluation of treated specimens provides important prognostic information and may guide subsequent chemotherapy. Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used in these tumors and standardized approaches to evaluate these specimens are needed. In this review, the various tumor regression scoring systems that have been used in these organs are described and their associations with clinical outcomes are discussed. Recommendations regarding how to handle and report the histologic findings in these resections specimens are provided.

AB - Neoadjuvant therapy is increasingly used to treat patients with a wide variety of malignancies. Histologic evaluation of treated specimens provides important prognostic information and may guide subsequent chemotherapy. Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used in these tumors and standardized approaches to evaluate these specimens are needed. In this review, the various tumor regression scoring systems that have been used in these organs are described and their associations with clinical outcomes are discussed. Recommendations regarding how to handle and report the histologic findings in these resections specimens are provided.

UR - http://www.scopus.com/inward/record.url?scp=85040183513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040183513&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2017.87

DO - 10.1038/modpathol.2017.87

M3 - Review article

C2 - 28776577

AN - SCOPUS:85040183513

VL - 31

SP - 4

EP - 23

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 1

ER -